XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Product Sales
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Product Sales Product Sales
Net product sales consist of the following:
Year Ended December 31,
(In millions)202220212020
EYLEA®
U.S.$6,264.6 $5,792.3 $4,947.2 
Libtayo®(a)
U.S.374.5 306.3 270.7 
ROW(b)
73.0 — —
Praluent®(c)
U.S.130.0 170.0 150.9
REGEN-COV®(d)
U.S.— 5,828.0 185.7 
Evkeeza®
U.S.48.6 18.4 — 
Inmazeb®
U.S.3.0 — — 
ARCALYST®(e)
U.S.— 2.2 13.1 
$6,893.7 $12,117.2 $5,567.6 
(a) Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.
(b) Rest of world ("ROW")
(c) Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.
(d) Net product sales of REGEN-COV in the United States relate to product sold in connection with the Company's agreements with the U.S. government. See Note 3 for further details.
(e) Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.
As of December 31, 2022 and 2021, the Company had $3.586 billion and $5.059 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December 31, 2022, 2021, and 2020. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
Year Ended December 31,
202220212020
Besse Medical, a subsidiary of AmerisourceBergen Corporation
55 %30 %51 %
McKesson Corporation28 %18 %32 %
U.S. government*43 %*
* Sales to the U.S. government represented less than 10% of total gross product revenue during the period
Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks, and discounts, distribution-related fees, and other sales-related deductions. Accruals for chargebacks and discounts are recorded as a direct reduction to accounts receivable. Accruals for rebates, distribution-related fees, and other sales-related deductions are recorded within accrued liabilities. The following table summarizes the provisions, and credits/payments, for sales-related deductions.
(In millions)Rebates, Chargebacks,
and Discounts		Distribution-
Related Fees		Other Sales-
Related Deductions		Total
Balance as of December 31, 2019$80.3 $46.4 $29.4 $156.1 
Provisions
762.9 279.9 94.1 1,136.9 
Credits/payments(641.0)(249.1)(78.7)(968.8)
Balance as of December 31, 2020202.2 77.2 44.8 324.2 
Provisions
1,047.1 363.6 150.4 1,561.1 
Credits/payments(1,034.7)(360.8)(127.6)(1,523.1)
Balance as of December 31, 2021214.6 80.0 67.6 362.2 
Provisions
1,537.3 431.1 141.1 2,109.5 
Credits/payments(1,398.0)(399.7)(127.2)(1,924.9)
Balance as of December 31, 2022$353.9 $111.4 $81.5 $546.8